Select Publications
Conference Papers
2015, 'Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/ refractory (PRR) and potentially platinum sensitive ROC receiving >= 3 lines of chemotherapy (PPS >= 3)-The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5536
,2015, 'Molecular profile comparison of endometrial, renal and ovarian clear cell carcinoma: Is it the same disease at different sites?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5595
,2015, 'Molecular profiling of mucinous epithelial ovarian carcinomas (mEOC): Opportunities for clinical trials.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5540
,2015, 'Phase 3 randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2-BRCA-associated locally advanced or metastatic breast cancer (BC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 51st Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.tps1102
,2015, 'TOPS - a randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, Chicago, presented at 2015 ASCO Annual Meeting, Chicago, 29 May 2015 - 02 June 2015, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358036902066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
,2015, 'What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient (BMOC pt) outcomes to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment?', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, IL, Chicago, 29 May 2015 - 02 June 2015, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5546
,2015, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy', in GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS INC ELSEVIER SCIENCE, pp. 8 - 8, http://dx.doi.org/10.1016/j.ygyno.2015.01.015
,2015, 'Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, AUSTRIA, Vienna, pp. S550 - S550, presented at European Cancer Congress, AUSTRIA, Vienna, http://dx.doi.org/10.1016/S0959-8049(16)31525-8
,2014, 'Breast cancer screening by women from BRCA1 & BRCA2 mutation positive families', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, presented at 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2014 - 13 December 2014, http://dx.doi.org/10.1158/1538-7445.SABCS14-P3-02-03
,2014, 'PARAGON- PHASE II STUDY OF AROMATASE INHIBITORS IN WOMEN WITH POTENTIALLY HORMONE RESPONSIVE RECURRENT/METASTATIC GYNAECOLOGICAL NEOPLASMS: ANZGOG 0903', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 167 - 167, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345350900278&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'A new patient-reported outcome measure for symptom benefit with chemotherapy: the Measure of Ovarian Symptoms and Treatment concerns (MOST)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 20 - 20, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'A PILOT INTEGRATED ANALYSIS OF LONG-TERM BENEFIT OF OLAPARIB IN OVARIAN CANCER: RESULTS OF FEASIBILITY TESTING.', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 141 - 142, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500119&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'BRCA1/2 MUTATIONS ASSOCIATED WITH PROGRESSION FREE SURVIVAL IN OVARIAN CANCER PATIENTS WHO RECEIVED PAZOPANIB OR PLACEBO IN THE AGO-OVAR16 STUDY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 40 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500032&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'COMPARISON OF OVARIAN AND RENAL CLEAR CELL CARCINOMA BY COMPREHENSIVE TUMOR PROFILING', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 148 - 148, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500123&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'DRY EYES & AIS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 33 - 33, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344745100087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'DRY EYES & AIS', in CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, WILEY-BLACKWELL, pp. 65 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344530600094&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'GAMUT - GENOMIC ANALYSIS OF MUCINOUS TUMOURS', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 129 - 130, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500110&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'HIGH-GRADE MUCINOUS OVARIAN CANCER: CLINICAL AND MOLECULAR ANNOTATION OF A RARE CANCER, ORIGINS AND THERAPEUTIC POTENTIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 426 - 427, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500300&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'OVARIAN CANCER SCREENING BY AUSTRALIAN WOMEN FROM FAMILIES WITH BRCA1 OR BRCA2 MUTATIONS', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 223 - 224, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'PARAGON (ANZGOG0903): PHASE 2 STUDY OF ANASTROZOLE IN WOMEN WITH ESTROGEN(ER)/PROGESTERONE (PR) POSITIVE PLATINUM RESISTANT/REFRACTORY RECURRENT OVARIAN CANCER (PRROC)', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, pp. 38 - 38, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344966500030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'PEGASUS - Prevalence and severity of genitourinary symptoms and impact on sexual function and quality of life in postmenopausal women receiving adjuvant endocrine therapy for early stage breast cancer - A prospective study', in MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, LIPPINCOTT WILLIAMS & WILKINS, DC, Washington, pp. 1364 - 1364, presented at 25th Annual Meeting of the North-American-Menopause-Society, DC, Washington, 15 October 2014 - 18 October 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345846600165&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'A phase III trial of adjuvant chemotherapy following chemoradialion as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/G0G0274/RTOG1174).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000358613202170&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'Characterization of ovarian cancer long-term responders on olaparib.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5534
,2014, 'Measuring subjective improvement of palliative chemotherapy in women with platinum-resistant or -refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/GCIG/PoCoG).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5615
,2014, 'Molecular profiling of clear cell ovarian carcinoma.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5516
,2014, 'The PARAGON phase 2 trial of anastrozole us women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5621
,2014, 'The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab no patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps5627
,2014, 'Dry Eyes and AIs', in INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOC RESEARCH VISION OPHTHALMOLOGY INC, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000433199700013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'QUALITY OF REPORTING OF PATIENT RATED OUTCOMES IN OVARIAN CANCER CLINICAL TRIALS: A SYSTEMATIC REVIEW', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 61 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500048&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'THE ANZUP PHASE 3 ACCELERATED BEP TRIAL: A RANDOMISED PHASE 3 TRIAL OF ACCELERATED VERSUS STANDARD BEP CHEMOTHERAPY FOR PATIENTS WITH INTERMEDIATE AND POOR-RISK METASTATIC GERM CELL TUMOURS', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 61 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'BARRIERS TO RECRUITMENT FOR A POST-CANCER FATIGUE INTERVENTION STUDY - THE TOPS TRIAL', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 116 - 116, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'CARING FOR WOMEN WITH OVARIAN CANCER IN THE LAST YEAR OF THEIR LIFE: IMPACT ON THE CAREGIVER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 103 - 103, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800141&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'PHYSICAL ACTIVITY (PA) PARTICIPATION FOR WOMEN WITH OVARIAN CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 114 - 114, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800170&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Psychosocial Predictors of Survival in Invasive Ovarian Cancer: A Population-Based Prospective Study', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, pp. 46 - 47, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325687200070&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'QUALITATIVE ANALYSIS OF KNOWLEDGE, ATTITUDES AND EXPERIENCES REGARDING URINARY SYMPTOMS AMONG POSTMENOPAUSAL WOMEN TAKING AROMATASE INHIBITORS FOR EARLY STAGE BREAST CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 143 - 143, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800262&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Quality of Life, Distress and Coping in Women With Ovarian Cancer: A Population Based, Longitudinal Study', in PSYCHO-ONCOLOGY, WILEY-BLACKWELL, pp. 44 - 44, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325687200066&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Analyzing patient-reported outcome (PRO) endpoints in advanced cancer clinical trials: responder analysis versus mixed model for repeated measures (MMRM) illustrated with results from the AURELIA ovarian cancer trial', in QUALITY OF LIFE RESEARCH, SPRINGER, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000209359000043&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Mucinous ovarian tumors: Are they all the same?', in CLINICAL CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1078-0432.OVCA13-A3
,2013, 'PHYSICAL ACTIVITY AND SLEEP DISTURBANCES FOR WOMEN WITH RECURRENT OVARIAN CANCER UNDERGOING CHEMOTHERAPY', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330379502010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'PROGRESSION-FREE SURVIVAL BY GCIG CRITERIA: ANALYSIS OF THE SECONDARY ENDPOINT OF THE AGO-OVAR16 TRIAL', in INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000330379500111&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S161 - S161, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843601074&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S712 - S713, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843604308&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Quality of life in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC) receiving either pazopanib monotherapy or placebo after first-line chemotherapy: AGO-OVAR16 results', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S713 - S713, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843604309&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'DO BRCA1 AND BRCA2 MUTATION CARRIERS HAVE EARLIER NATURAL MENOPAUSE THAN THEIR NON-CARRIER RELATIVES?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 54 - 54, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300026&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'MUCINOUS OVARIAN TUMOURS: IS ONE OF THESE THINGS NOT LIKE THE OTHERS?', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 45 - 46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'RISK-REDUCING BEHAVIOUR OF FEMALE BRCA1 AND BRCA2 MUTATION CARRIERS; LONG-TERM FOLLOW-UP OF PARTICIPANTS IN kConFab', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 45 - 45, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419602056&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419602019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Olaparib monotherapy in patients with advanced cancer and a germ-line BRAC1/2 mutation: An open-label phase II study', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419600435&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419605470&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,